Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy Mice | Zendy

Jill A. RafaelFortney | Zendy; Neeraj Chimanji | Zendy; Kevin E. Schill | Zendy; Christopher Martin | Zendy; Jason D. Murray | Zendy; Ranjit Ganguly | Zendy; Jenna E. Stangland | Zendy; Tam Tran | Zendy; Ying Xu | Zendy; Benjamin D. Canan | Zendy; Tessily A. Mays | Zendy; Dawn A. Delfín | Zendy; Paul M.L. Janssen | Zendy; Subha V. Raman | Zendy

Open Access

Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy Mice

Author(s) -

Jill A. RafaelFortney,

Neeraj Chimanji,

Kevin E. Schill,

Christopher Martin,

Jason D. Murray,

Ranjit Ganguly,

Jenna E. Stangland,

Tam Tran,

Ying Xu,

Benjamin D. Canan,

Tessily A. Mays,

Dawn A. Delfín,

Paul M.L. Janssen,

Subha V. Raman

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.031716

Subject(s) - medicine , duchenne muscular dystrophy , dystrophin , lisinopril , endocrinology , cardiomyopathy , spironolactone , cardiac function curve , heart failure , muscular dystrophy , skeletal muscle , myopathy , myocardial fibrosis , ejection fraction , cardiology , blood pressure , angiotensin converting enzyme

Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death. Because DMD patients show myocardial fibrosis well before functional impairment, we postulated that earlier treatment using drugs with antifibrotic effect may be beneficial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research